What this study is
The aim of the study is to compare the effect of CirrhosisRx, a novel clinical decision support (CDS) system for inpatient cirrhosis care, versus "usual care" on adherence to national quality measures and clinical outcomes for hospitalized patients with cirrhosis.
What's being tested
- CirrhosisRx CDS
Intervention · OTHER
CirrhosisRx is a cirrhosis-specific CDS that organizes clinical data into clinically relevant groupings and links them to order sets consistent with national practice guidelines for inpatient cirrhosis care.
Study details
- Official title
- Pragmatic Randomized Controlled Trial to Evaluate the Effect of CirrhosisRx, a Novel Clinical Decision Support System, on Guideline-adherence and Clinical Outcomes for Patients With Cirrhosis
- Sponsor
- University of California, San Francisco
- Conditions
- Cirrhosis · Decision Support Systems, Clinical
- Enrolling
- 2,106 people
- Starts
- 2025-01-14
- Est. completion
- 2027-01
- Design
- Open-label, randomized, crossover
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- All adult (age ≥ 18 years) patients who have cirrhosis identified based on 1+ chronic liver disease and 1+ cirrhosis (or its complications) International Classification of Diseases, Revision 10 diagnosis codes OR mention of cirrhosis or portal hypertension (or their complications) in clinical documentation admitted at our institution.
You can't join if
- Children (age < 18 years)
- Patients who do not meet the cirrhosis definition criteria as noted above
- Ambulatory patients
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openUniversity of California San Francisco Medical Center
San Francisco, California, United States
- Jin Ge, MD, MBA · Contact415-502-8070jin.ge@ucsf.edu
Recruiting
Study team
Sponsor
University of California, San Francisco
Study ID 23-39379
Principal investigator
Jin Ge, MD, MBA
University of California, San Francisco
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.